Feasibility and tolerability of bevacizumab: a retrospective study in Japanese ovarian cancer patients

Purpose of investigation: To determine the probability of adverse events following bevacizumab (BV) treatment for advanced/recurrent ovarian, fallopian, and peritoneal cancers in Japanese patients. Materials and Methods: The authors retrospectively reviewed medical records of 35 patients. Results: One patient (2.9%) showed a grade 4 gastrointestinal perforation. Grade 1 or 3 gastrointestinal fistula was present in one patient each, whereas one patient had grade 5 tumor hemorrhage. In univariate logistic regression analysis for any grade of gastrointestinal perforation and fistula, the number of prior regimens and period from diagnosis to BV initiation were significant in univariate (p = 0.02 and p = 0.02, respectively) and multivariate (p = 0.02 and p = 0.02, respectively) logistic regression analyses. Conclusions: BV might be tolerable for Japanese patients. In patients where BV is initiated after long periods post-diagnosis or who undergo prior chemotherapy regimens, BV should be used carefully and there should be diligent monitoring for perforations.

Ovarian neoplasms; Bevacizumab; Asian Continental Ancestry Group; Intestinal perforation; Chemotherapy.

[1] Burger R.A., Brady M.F., Rhee J., Sovak M.A., Kong G., Nguyen H.P., Bookman M.A.: “Independent radiologic review of the Gynecologic Oncology Group Study 0218, a phase III trial of bevacizumab in the primary treatment of advanced epithelial ovarian, primary peritoneal, or fallopian tube cancer”. Gynecol. Oncol., 2013, 131, 21.

[2] Aghajanian C., Blank S.V., Goff B.A., Judson P.L., Teneriello M.G., Husain A., et al.: “OCEANS: a randomized, double-blind, placebocontrolled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer”. J. Clin. Oncol., 2012, 30, 2039.

[3] Pujade-Lauraine E., Hilpert F., Weber B., Reuss A., Poveda A., Kristensen G., et al.: “Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA openlabel randomized phase III trial”. J. Clin. Oncol., 2014, 32, 1302.

[4] Stark D., Nankivell M., Pujade-Lauraine E, Kristensen G., Elit L., Stockler M., et al.: “Standard chemotherapy with or without bevacizumab in advanced ovarian cancer: quality-of-life outcomes from the International Collaboration on Ovarian Neoplasms (ICON7) phase 3 randomised trial”. Lancet Oncol., 2013, 14, 236.

[5] Perren T.J., Swart A.M., Pfisterer J., Ledermann J.A., Pujade-Lauraine E., Kristensen G., et al.: “A phase 3 trial of bevacizumab in ovarian cancer”. N. Engl. J. Med., 2011, 365, 2484.

[6] Stockler M.R., Hilpert F., Friedlander M., King M.T., Wenzel L., Lee C.K., et al.: “Patient-reported outcome results from the open-label phase III AURELIA trial evaluating bevacizumab-containing therapy for platinum-resistant ovarian cancer”. J. Clin. Oncol., 2014, 32, 1309.

[7] Cannistra S.A., Matulonis U.A., Penson R.T., Hambleton J., Dupont J., MackeyH., et al.: “Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer”. J. Clin. Oncol., 2007, 25, 5180.

[8] Calvert A.H., Newell D.R., Gumbrell L.A., O’Reilly S., Burnell M., Boxall F.E., et al.: “Carboplatin dosage: prospective evaluation of a simple formula based on renal function”. J..Clin. Oncol., 1989, 7, 1748.

[9] Jelliffe R.W: “Letter: Creatinine clearance: bedside estimate”. Ann. Intern. Med., 1973, 79, 604.

[10] Kaplan E.L., Meyer P.: “Nonparametric estimation from incomplete observations”. J. Am. Stat. Assoc., 1958, 53, 457.

[11] Han E.S., Monk B.J.: “What is the risk of bowel perforation associated with bevacizumab therapy in ovarian cancer?” Gynecol. Oncol., 2007, 105, 3.

[12] Rubesin S.E., Levine M.S.: “Radiologic diagnosis of gastrointestinal perforation”. Radiol. Clin. North. Am., 2003, 41, 1095.

[13] Townsend C., Beauchamp D., Evers M., Mattox K., Sabiston D.: “Chapter 48: Colon and Rectum”. In: Townsend C. Jr., Beauchamp R.D., Evers B.M., Mattox K.L. 17th ed. Sabiston Textbook of Surgery, Pennsylvania: Saunders, 2004, 1420.

[14] See H.T., Freedman R.S., Kudelka A.P., Burke T.W., Gershenson D.M., Tangjitgamol S., et al.: “Retrospective review: re-treatment of patients with ovarian cancer with carboplatin after platinum resistance”. In.t J. Gynecol, Cancer., 2005, 15, 209.

[15] Pignata S., Ferrandina G., Scarfone G., Scollo P., Odicino F., Selvaggi L., et al.: “Extending the platinum-free interval with a nonplatinum therapy in platinum-sensitive recurrent ovarian cancer. Results from the SOCRATES Retrospective Study”. Oncology, 2006, 71, 320.